Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Kakafika AI, Liberopoulos EN, Karagiannis A, Athyros VG, Mikhailidis DP. Kakafika AI, et al. Curr Vasc Pharmacol. 2006 Jul;4(3):175-83. doi: 10.2174/157016106777698432. Curr Vasc Pharmacol. 2006. PMID: 16842135 Review.
Statins for the prevention of first or recurrent stroke.
Athyros VG, Kakafika AI, Tziomalos K, Papageorgiou AA, Karagiannis A. Athyros VG, et al. Among authors: kakafika ai. Curr Vasc Pharmacol. 2008 Apr;6(2):124-33. doi: 10.2174/157016108783955365. Curr Vasc Pharmacol. 2008. PMID: 18393914 Review.
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.
Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Athyros VG, et al. Curr Vasc Pharmacol. 2011 Nov;9(6):647-57. doi: 10.2174/157016111797484080. Curr Vasc Pharmacol. 2011. PMID: 21476961 Clinical Trial.
Fibrinogen: a predictor of vascular disease.
Kakafika AI, Liberopoulos EN, Mikhailidis DP. Kakafika AI, et al. Curr Pharm Des. 2007;13(16):1647-59. doi: 10.2174/138161207780831310. Curr Pharm Des. 2007. PMID: 17584095 Review.
Platelets and vascular risk: an option for treatment.
Jagroop IA, Kakafika AI, Mikhailidis DP. Jagroop IA, et al. Among authors: kakafika ai. Curr Pharm Des. 2007;13(16):1669-83. doi: 10.2174/138161207780831383. Curr Pharm Des. 2007. PMID: 17584097 Review.
Smoking and aortic diseases.
Kakafika AI, Mikhailidis DP. Kakafika AI, et al. Circ J. 2007 Aug;71(8):1173-80. doi: 10.1253/circj.71.1173. Circ J. 2007. PMID: 17652877 Free article. Review.
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D, Karagiannis A, Kakafika AI, Tziomalos K, Elisaf M. Athyros VG, et al. Among authors: kakafika ai. Metabolism. 2005 Aug;54(8):1065-74. doi: 10.1016/j.metabol.2005.03.010. Metabolism. 2005. PMID: 16092057 Clinical Trial.
65 results